After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, KALV falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of KalVista Pharmaceuticals Inc is $571.28M. A total of 0.68 million shares were traded on the day, compared to an average of 540.67K shares.
In the most recent transaction, Venrock Healthcare Capital Par bought 25,000 shares of KALV for 9.42 per share on Apr 09 ’25. After the transaction, the 10% Owner now owns 5,303,985 company shares. In a previous transaction on Mar 07 ’25, Palleiko Benjamin L sold 6,669 shares at 11.97 per share. KALV shares that CHIEF EXECUTIVE OFFICER owns now total 287,811.
Among the insiders who sold shares, Audhya Paul K. disposed of 2,394 shares on Feb 24 ’25 at a per-share price of $10.02. This resulted in the CHIEF MEDICAL OFFICER holding 102,940 shares of KALV after the transaction. In another insider transaction, Yea Christopher sold 1,918 shares at $10.02 per share on Feb 24 ’25. Company shares held by the CHIEF DEVELOPMENT OFFICER now total 93,952.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, KALV has a high of $15.50 and a low of $7.30.
As of this writing, KALV has an earnings estimate of -$0.83 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$0.73 per share and a lower estimate of -$0.95.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. KALV’s latest balance sheet shows that the firm has $166.20M in Cash & Short Term Investments as of fiscal 2022. There were $8.19M in debt and $11.58M in liabilities at the time. Its Book Value Per Share was $2.93, while its Total Shareholder’s Equity was $185.09M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KALV is Buy with a score of 4.90.
